"A Study of a Deuterated Psilocin Analog (CYB003) in Humans With Major Depressive Disorder" (APPROACH)

May 4, 2026 updated by: Cybin IRL Limited

A Phase III, Placebo-Controlled, Randomized, Double-Blind Trial of Oral Doses of CYB003 to Assess Combined Safety and Efficacy in Humans With Major Depressive Disorder

The purpose of this study is to examine the efficacy, safety, and tolerability of CYB003 compared to matching placebo as adjunctive treatment in participants with MDD.

Study Overview

Status

Recruiting

Conditions

Intervention / Treatment

Study Type

Interventional

Enrollment (Estimated)

220

Phase

  • Phase 3

Contacts and Locations

This section provides the contact details for those conducting the study, and information on where this study is being conducted.

Study Contact

Study Locations

  • United States
    • Arizona
      • Phoenix, Arizona, United States, 85022
      • Phoenix, Arizona, United States, 85050
        • Recruiting
        • Mountain Clinical Trials
        • Principal Investigator:
          • Ruchir Gupta
      • Tucson, Arizona, United States, 85704
        • Recruiting
        • Noble Clinical Research
        • Contact:
        • Principal Investigator:
          • Brandon Yates
      • Tucson, Arizona, United States, 85715
        • Recruiting
        • Del Sol Research Management
        • Contact:
          • Phone Number: 520-257-3881
        • Principal Investigator:
          • Steven Bupp
    • California
      • Bellflower, California, United States, 90706
        • Recruiting
        • CenExel CIT (Clinical Innovations, Inc)
        • Contact:
          • Phone Number: 949-350-0492
        • Principal Investigator:
          • Robert Bota
      • La Jolla, California, United States, 92037
        • Recruiting
        • Kadima Neuropsychiatry Institute
        • Principal Investigator:
          • David Feifel
        • Contact:
      • Los Angeles, California, United States, 90025
        • Recruiting
        • Bespoke Treatment/Lipov Medical Group
        • Principal Investigator:
          • Nima Fahimian
        • Contact:
          • Phone Number: 833-461-1045
      • Montclair, California, United States, 91763
        • Recruiting
        • Catalina Research Institute
        • Principal Investigator:
          • Stephen Volk
      • Oceanside, California, United States, 92056
        • Recruiting
        • Excell Research, Inc
        • Principal Investigator:
          • Sherry Soefje
        • Contact:
          • Phone Number: 760-758-2222
      • San Francisco, California, United States, 94114
        • Recruiting
        • Open Mind Therapeutics
        • Contact:
          • Phone Number: 415-669-6287
        • Principal Investigator:
          • Sidney Edsall
      • San Juan Capistrano, California, United States, 92675
        • Recruiting
        • Inland Psychiatric Medical Group Inc
        • Contact:
          • Phone Number: 909-488-9116
        • Principal Investigator:
          • Neelima Kunam
    • Colorado
      • Denver, Colorado, United States, 80209
        • Recruiting
        • Mountain View Clinical Research
        • Contact:
          • Phone Number: 720-941-9363
        • Principal Investigator:
          • Sara Markey
      • Evergreen, Colorado, United States, 80439
    • Florida
      • Hollywood, Florida, United States, 33024
        • Recruiting
        • Research Centers of America
        • Contact:
          • Phone Number: 954-990-7649
        • Principal Investigator:
          • Edwin Gomez
      • Maitland, Florida, United States, 32751
        • Recruiting
        • K2 Medical Research-Maitland
        • Contact:
          • Phone Number: 407-676-5252
        • Principal Investigator:
          • Sejal Patel
      • Miami, Florida, United States, 33135
        • Recruiting
        • Floridian Neuroscience Institute
        • Contact:
          • Phone Number: 786-238-7099
        • Principal Investigator:
          • Emilio Mantero
      • North Miami, Florida, United States, 33161
      • Orlando, Florida, United States, 32807
        • Recruiting
        • Combined Research Orlando Phase I-IV
        • Principal Investigator:
          • Eric Carbonell
        • Contact:
      • Orlando, Florida, United States, 32801
        • Recruiting
        • Clinical Neuroscience Solutions, Inc
        • Principal Investigator:
          • Robert Molpus
        • Contact:
      • Orlando, Florida, United States, 32803
        • Recruiting
        • Charter Research
        • Principal Investigator:
          • Jorel Martinez
        • Contact:
          • Phone Number: 407-337-3000
      • Tampa, Florida, United States, 33634
        • Recruiting
        • K2 Medical Research - Tampa
        • Contact:
          • Phone Number: 813-500-5252
        • Principal Investigator:
          • Kelly Yokum
    • Georgia
      • Atlanta, Georgia, United States, 30331
        • Recruiting
        • Atlanta Center for Medical Research, CenExel
        • Contact:
        • Principal Investigator:
          • Elyssa Barron, MD
      • Decatur, Georgia, United States, 30330
        • Recruiting
        • CenExel iResearch Atlanta
        • Principal Investigator:
          • Kimball Johnson, MD
        • Contact:
        • Contact:
      • Savannah, Georgia, United States, 31405
        • Recruiting
        • CenExel iResearch Savannah
        • Contact:
          • Phone Number: 912-744-0800
        • Principal Investigator:
          • Nancy Backus
    • Illinois
      • Chicago, Illinois, United States, 60640
        • Recruiting
        • Uptown Research Institute
        • Principal Investigator:
          • John Sonnenberg
        • Contact:
      • Chicago, Illinois, United States, 60640
        • Recruiting
        • Great Lakes Clinical Trials, DBA Flourish Research
        • Principal Investigator:
          • Jeff Ross
        • Contact:
          • Phone Number: 1 312-931-8883
      • Skokie, Illinois, United States, 60076
        • Recruiting
        • Psychiatric Medicine Associates, LLC
        • Principal Investigator:
          • John Zajecka
        • Contact:
    • Louisiana
      • New Orleans, Louisiana, United States, 70115
        • Recruiting
        • DelRicht Research
        • Contact:
          • Phone Number: 504-336-2667
        • Principal Investigator:
          • Caroline Campion
      • New Orleans, Louisiana, United States, 70115
        • Not yet recruiting
        • Atlas Psychiatric
        • Principal Investigator:
          • Nicholas Pejic, M.D.
    • Maryland
      • Rockville, Maryland, United States, 20850
        • Recruiting
        • Sunstone Medical, PC
        • Contact:
          • Phone Number: 301-750-3401
        • Principal Investigator:
          • Manish Agrawal
    • Massachusetts
      • Boston, Massachusetts, United States, 02472
        • Recruiting
        • Adams Clinical
        • Contact:
          • Phone Number: 617-744-8542
        • Principal Investigator:
          • Daniel Rutrick
      • Boston, Massachusetts, United States, 02116
        • Recruiting
        • Adams Clinical Boston
        • Principal Investigator:
          • Darin Dougherty
        • Contact:
      • Springfield, Massachusetts, United States, 01103
        • Recruiting
        • Elixia Health
        • Principal Investigator:
          • Adnan Dahdul
        • Contact:
    • Nevada
      • Las Vegas, Nevada, United States, 89119
        • Recruiting
        • Redbird Research, LLC
        • Principal Investigator:
          • Jelena Kunovac
        • Contact:
      • Las Vegas, Nevada, United States, 89121
        • Terminated
        • Oasis Clinical Trials
    • New Jersey
      • Princeton, New Jersey, United States, 08540
        • Recruiting
        • Global Medical Institutes, Princeton Medical Institute
        • Principal Investigator:
          • Sanjay Varma
        • Contact:
          • Phone Number: 609-921-6050
    • New York
      • New York, New York, United States, 100029
        • Recruiting
        • Adams Clinical Harlem
        • Principal Investigator:
          • Rachel Noone
        • Contact:
      • The Bronx, New York, United States, 10461
        • Recruiting
        • Adams Clinical Bronx
        • Principal Investigator:
          • Shama Farooq
        • Contact:
    • North Carolina
      • Monroe, North Carolina, United States, 28112
        • Recruiting
        • Monroe Biomedical Research
        • Principal Investigator:
          • Rasheed Onafuye
        • Contact:
          • Phone Number: 704-290-3556
    • Ohio
      • North Canton, Ohio, United States, 44720
        • Recruiting
        • Neurobehavioral Clinical Research
        • Contact:
          • Phone Number: 330-493-1118
        • Principal Investigator:
          • Shishuka Malhotra
    • Tennessee
      • Memphis, Tennessee, United States, 38119
        • Recruiting
        • Clinical Neuroscience Solutions, CNS Healthcare
        • Principal Investigator:
          • Valerie Arnold
        • Contact:
          • Phone Number: 901-843-1045
    • Texas
      • DeSoto, Texas, United States, 75115
        • Recruiting
        • InSite Clinical Research, LLC
        • Contact:
          • Phone Number: 972-283-6286
        • Principal Investigator:
          • Rajinder Shiwach
      • Houston, Texas, United States, 77433
        • Recruiting
        • Zillan Clinical Research
        • Principal Investigator:
          • Flavia Thomas
        • Contact:
          • Phone Number: 213-245-5462
      • Plano, Texas, United States, 75093
        • Withdrawn
        • AIM Trials
    • Utah
      • Murray, Utah, United States, 84107
        • Recruiting
        • Cedar Clinical Research
        • Contact:
        • Contact:
        • Principal Investigator:
          • Paul Thielking
      • Orem, Utah, United States, 84058
        • Recruiting
        • Inner Space Research, LLC
        • Principal Investigator:
          • Reid Robison
        • Contact:

Participation Criteria

Researchers look for people who fit a certain description, called eligibility criteria. Some examples of these criteria are a person's general health condition or prior treatments.

Eligibility Criteria

Ages Eligible for Study

  • Adult
  • Older Adult

Accepts Healthy Volunteers

No

Description

Inclusion Criteria:

Participants must meet all the following criteria to be included in the trial:

  • Aged 18 to 85 years inclusive, at Screening
  • Participant has a diagnosis of MDD (single or recurrent episode as defined by DSM-5 TR [if single episode, duration of ≥4 weeks and ≤24 months] and established as per evaluation by the Investigator. The first MDD episode must have occurred prior to age 60.
  • Depression is of moderate to severe degree at Screening and Baseline, independently confirmed by additional clinical assessments
  • Participant has been on a stable dose of a single antidepressant medication at an adequate dose (label specified) for an adequate duration in the last month prior to Screening and has had an inadequate response (less than 50% improvement), as judged by the Investigator.
  • Participant has a body mass index (BMI) of 40 kg/m2 or less (BMI ≤ 40 kg/m2), inclusive, at Screening.
  • Participant is able to refrain from nicotine use during the dosing session (up to 8 hours)
  • Registered with a healthcare professional who can confirm the diagnosis and previous treatments received by the participant.
  • Participants capable of producing sperm must use a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication, if their partner is a person of childbearing potential.
  • Participants of childbearing potential who have a partner capable of producing sperm must agree to use a highly effective method of contraception (i.e., failure rate less than 1% when used consistently and correctly) in combination with the use of a condom plus spermicide during the trial and for 12 weeks after their final dose of trial medication. Such participants must have a negative pregnancy test at Screening and Day 1 prior to dosing.
  • Female participants who were capable of producing eggs (ova) must agree that the only exclusion from the requirement for contraception during the trial is to be postmenopausal or permanently sterile following hysterectomy, bilateral salpingectomy, or bilateral oophorectomy. Postmenopausal is defined as spontaneous amenorrhea for at least 12 months, and a serum follicle-stimulating hormone level in the menopausal range, unless the participant is taking hormone replacement therapy or is using hormonal contraception.
  • Participant has provided written informed consent, which includes compliance with the requirements and restrictions listed in the informed consent form.

Exclusion Criteria:

Participants with any of the following characteristics/conditions will be excluded from trial participation:

  • Current or previously diagnosed schizophrenia spectrum or other psychotic disorders, including schizophrenia, schizoaffective disorder, schizotypal disorder, schizophreniform disorder, brief psychotic disorder, current or previous history of bipolar disorder, or current borderline personality disorder.
  • Participants with a medical diagnosis of attention deficit hyperactivity disorder (ADHD) will be excluded if currently taking medication for ADHD
  • Family history of schizophrenia, schizoaffective disorder, or bipolar disorder type 1 (first degree relatives).
  • Significant suicide risk within the past 6 months, during the Screening Period, or at Baseline; or (b) suicidal behaviors within 12 months of Screening; or (c) clinical assessment of significant suicidal risk during clinical interview; or (d) non-suicidal self-injury within 12 months of Screening.
  • Current or previous diagnosis of treatment-resistant MDD, defined as failure to respond to 2 or more antidepressant treatments of 2 different classes given at an adequate dose (label specified) for an adequate duration as judged by the Investigator and clinical interview.
  • Has had electroconvulsive treatment, transcranial magnetic stimulation, deep brain stimulation, or vagal nerve stimulation for any episode of MDD in the last 6 months.
  • Currently receiving a monoamine oxidase inhibitor, tricyclic antidepressant, mirtazapine, trazodone, moclobemide, buspirone, ketamine or S-ketamine, or an antipsychotic or mood stabilizer for MDD. Note: if receiving these medications for another indication, they must be discontinued ≥ 14 days or 5 half-lives, whichever is longer, prior to Day 1.
  • Participant report of (or if available in medical record) exposure to psilocin, or 5-HT2a receptor agonists, or any other psychedelics, such as ayahuasca, mescaline, lysergic acid diethylamide, peyote, or 3,4-methylenedioxymethamphetamine, more than 10 times over the participant's lifetime or any psychedelic use within 12 months prior to Screening.
  • Participant report of (or if available in medical record) treatment with ketamine or S-ketamine use within 6 months prior to Screening.
  • Clinically relevant history of abnormal physical health interfering with the trial as determined by medical history and physical examinations obtained during Screening as judged by the Investigator (including but not limited to, neurological, cardiovascular, respiratory, gastrointestinal [including dyspepsia or gastroesophageal reflux disease], hepatic, or renal disorder).
  • Participants with renal insufficiency.
  • Has hypothyroidism or hyperthyroidism, unless controlled on appropriate medication.
  • Current diagnosis of uncontrolled hypertension or an arrhythmia, or clinically relevant abnormal results for heart rate or blood pressure
  • History or clinical evidence of any disease and/or existence of any surgical or medical condition which might interfere with the absorption, distribution, metabolism, or excretion of the trial medication.
  • Participant has a presence or relevant history of organic brain disorders (e.g., epilepsy, seizure, intracranial hypertension, intracranial bleed and aneurysmal disease, brain tumor or other medical conditions associated with seizures or convulsions).
  • Known sensitivity to psilocin and/or any excipients present in the formulation.
  • Participant is taking or has taken OTC doses of 5-HTP or St John's Wort within 14 days prior to trial medication administration.
  • The participant has participated in a clinical trial and has received a medication or a new chemical entity within 12 weeks prior to dosing with the current trial medication. Participants who have completed observational or non-interventional studies will be allowed.
  • Participants capable of producing sperm who will not abstain from sperm donation between first dosing and 12 weeks after final dosing.
  • Participants of childbearing potential who are pregnant, breastfeeding, planning to conceive or unwilling to abstain from egg (ova) donation between first dosing and 12 weeks after final dosing.
  • History of serotonin syndrome.
  • Unwilling to consent to audio and video recording of psychological support and dosing sessions.
  • Staff and family members of Cybin IRL Limited, investigator sites, contract research organization or other vendors.

Study Plan

This section provides details of the study plan, including how the study is designed and what the study is measuring.

How is the study designed?

Design Details

  • Primary Purpose: Treatment
  • Allocation: Randomized
  • Interventional Model: Parallel Assignment
  • Masking: Quadruple

Arms and Interventions

Participant Group / Arm
Intervention / Treatment
Experimental: Experimental Arm A: CYB003 in 2 of 2 Dosing Sessions
Arm A participants will receive 16 mg of CYB003 in 2 of 2 medicine sessions, approximately three weeks apart. All Arm A participants will continue on their current antidepressants and receive psychological support throughout the study.
Behavioral: Psychological Support
Manualized psychological support performed by facilitators
Drug: CYB003
CYB003 is a Deuterated Psilocin Analog.
Placebo Comparator: Placebo Comparator Arm B: Placebo in 2 of 2 Dosing Sessions
Arm B participants will receive placebo in 2 of 2 Dosing Sessions, approximately three weeks apart. All Arm B participants will continue on their current antidepressants and receive psychological support throughout the study. Non-responders will be eligible to receive CYB003 in a subsequent extension trial.
Drug: Placebo
Placebo
Behavioral: Psychological Support
Manualized psychological support performed by facilitators

What is the study measuring?

Primary Outcome Measures

Outcome Measure
Measure Description
Time Frame
Montgomery-Åsberg Depression Rating Scale (MADRS)
Time Frame: Screening Day-45, Baseline Day-1, Day 2, Day 10, Day 21, Day 23, Day 31, and Day 42 (End of Treatment)
The MADRS is a 10-item scale with ratings based on a clinical interview which moves from broadly phrased questions about symptoms to more detailed ones allowing a precise rating of severity.
Screening Day-45, Baseline Day-1, Day 2, Day 10, Day 21, Day 23, Day 31, and Day 42 (End of Treatment)

Secondary Outcome Measures

Outcome Measure
Measure Description
Time Frame
The Beck Depression Inventory-Second Edition (BDI-II)
Time Frame: Baseline Day-1, Day 21, and Day 42 (End of Treatment)
The Beck Depression Inventory-Second Edition (BDI-II) is a 21-question multiple-choice self-report inventory, assessing depressive symptoms and severity.
Baseline Day-1, Day 21, and Day 42 (End of Treatment)
The Clinical Global Impression Scale (CGI-S)
Time Frame: Screening Day-45, Baseline Day-1, and Day 42 (End of Treatment)
The Clinical Global Impression Scale is a clinician-rated instrument comprised of 3 global measures: severity of illness, global improvement, and efficacy index. Only the severity of illness and global improvement measures will be utilized for this trial.
Screening Day-45, Baseline Day-1, and Day 42 (End of Treatment)
The Generalized Anxiety Disorder 7-item scale (GAD-7)
Time Frame: Baseline Day-1, Day 21, and Day 42 (End of Treatment)
The Generalized Anxiety Disorder 7-item scale (GAD-7) is a 7-item self-reported assessment that measures the severity of generalized anxiety disorder symptoms.
Baseline Day-1, Day 21, and Day 42 (End of Treatment)
The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF)
Time Frame: Baseline Day-1, Day 21, and Day 42 (End of Treatment)
The original Quality of Life Enjoyment and Satisfaction Questionnaire is a 93 item, participant facing, self-reported measure used to evaluate intervention-related changes in quality of life, divided into the following sections: physical health, feelings, work, household duties, school, leisure time activities, social relations, and general activities. The Quality of Life Enjoyment and Satisfaction Questionnaire - Short Form (Q-LES-Q-SF) version will be used in this trial.
Baseline Day-1, Day 21, and Day 42 (End of Treatment)

Collaborators and Investigators

This is where you will find people and organizations involved with this study.

Sponsor

Cybin IRL Limited

Collaborators

Worldwide Clinical Trials

Investigators

  • Study Chair: Clinical Development, Cybin IRL Limited

Publications and helpful links

The person responsible for entering information about the study voluntarily provides these publications. These may be about anything related to the study.

Helpful Links

Study record dates

These dates track the progress of study record and summary results submissions to ClinicalTrials.gov. Study records and reported results are reviewed by the National Library of Medicine (NLM) to make sure they meet specific quality control standards before being posted on the public website.

Study Major Dates

Study Start (Actual)

December 17, 2024

Primary Completion (Estimated)

August 1, 2026

Study Completion (Estimated)

September 1, 2026

Study Registration Dates

First Submitted

August 20, 2024

First Submitted That Met QC Criteria

August 20, 2024

First Posted (Actual)

August 21, 2024

Study Record Updates

Last Update Posted (Actual)

May 6, 2026

Last Update Submitted That Met QC Criteria

May 4, 2026

Last Verified

May 1, 2026

More Information

Terms related to this study

Keywords

Additional Relevant MeSH Terms

Other Study ID Numbers

  • CYB003-002

Plan for Individual participant data (IPD)

Plan to Share Individual Participant Data (IPD)?

NO

Drug and device information, study documents

Studies a U.S. FDA-regulated drug product

Yes

Studies a U.S. FDA-regulated device product

No

product manufactured in and exported from the U.S.

No

This information was retrieved directly from the website clinicaltrials.gov without any changes. If you have any requests to change, remove or update your study details, please contact register@clinicaltrials.gov. As soon as a change is implemented on clinicaltrials.gov, this will be updated automatically on our website as well.

Clinical Trials on Major Depressive Disorder

Clinical Trials on Placebo

Search Similar Trials

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Uganda

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations

Subscribe